We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Protective Effects of Ipragliflozin, a Sodium-glucose Cotransporter 2 Inhibitor, on a Non-alcoholic Steatohepatitis Mouse Model.
- Authors
Masafumi Yamane; Tomomitsu Matono; Jun-ichi Okano; Ran Nagahara; Yukako Matsuki; Toshiaki Okamoto; Ken-ichi Miyoshi; Takaaki Sugihara; Takakazu Nagahara; Masahiko Koda; Hajime Isomoto
- Abstract
Background The options for the treatment of nonalcoholic steatohepatitis (NASH) are limited. We examined the effects of ipragliflozin, a sodium-glucose cotransporter 2 inhibitor, on the fatty liver Shionogi (FLS)-ob/ob mice, a non-alcoholic steatohepatitis mouse model. Methods FLS-ob/ob male mice were treated with vehicle (n = 10) and ipragliflozin (n = 8). Serum metabolic markers, histopathology of the liver, hepatic cholesterol and triglyceride levels and hepatic mRNA levels related to fibrosis, lipid metabolism and endoplasmic reticulum (ER) stress were compared between the two groups. Results The body weight and hepatic cholesterol and triglyceride levels were significantly decreased in the ipragliflozin group compared with the control group. Hepatic steatosis and fibrosis were significantly ameliorated by the treatment with ipragliflozin. Hepatic infiltration of macrophage, expression levels of 8-hydroxy- 2-deoxyguanosine (8-OHdG) and hepatic mRNA levels of ER stress markers were not significantly modulated by the treatment with ipragliflozin. Conclusion Ipragliflozin can be a therapeutic option for patients with NASH. The precise mechanisms of action need to be clarified in future studies.
- Subjects
SODIUM-glucose cotransporters; FATTY liver; LIVER disease treatment; DEOXYGUANOSINE; MESSENGER RNA; ENDOPLASMIC reticulum
- Publication
Yonago Acta Medica, 2019, Vol 62, Issue 1, p30
- ISSN
0513-5710
- Publication type
Article
- DOI
10.33160/yam.2019.03.005